Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)
Abstract: The FK506‐binding protein 51 (FKBP51) is a promising target in a variety of disorders including depression, chronic pain, and obesity. Previous FKBP51‐targeting strategies were restricted to occupation of the FK506‐binding site, which does not affect core functions of FKBP51. Here, we report the discovery of the first FKBP51 proteolysis targeting chimera (PROTAC) that enables degradation of FKBP51 abolishing its scaffolding function. Initial synthesis of 220 FKBP‐focused PROTACs yielded a plethora of active PROTACs for FKBP12, six for FKBP51, and none for FKBP52. Structural analysis of a binary FKBP12:PROTAC complex revealed the molecular basis for negative cooperativity. Linker‐based optimization of first generation FKBP51 PROTACs led to the PROTAC SelDeg51 with improved cellular activity, selectivity, and high cooperativity. The structure of the ternary FKBP51:SelDeg51:VCB complex revealed how SelDeg51 establishes cooperativity by dimerizing FKBP51 and the von Hippel‐Lindau protein (VHL) in a glue‐like fashion. SelDeg51 efficiently depletes FKBP51 and reactivates glucocorticoid receptor (GR)‐signalling, highlighting the enhanced efficacy of full protein degradation compared to classical FKBP51 binding.
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51) ; day:14 ; month:12 ; year:2023 ; extent:8
Angewandte Chemie / International edition. International edition ; (14.12.2023) (gesamt 8)
- Urheber
-
Geiger, Thomas M.
Walz, Michael
Meyners, Christian
Kuehn, Angela
Dreizler, Johannes
Sugiarto, Wisely O.
Maciel, Edvaldo V. S.
Zheng, Min
Lermyte, Frederik
Hausch, Felix
- DOI
-
10.1002/anie.202309706
- URN
-
urn:nbn:de:101:1-2023121514211248654545
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:38 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Geiger, Thomas M.
- Walz, Michael
- Meyners, Christian
- Kuehn, Angela
- Dreizler, Johannes
- Sugiarto, Wisely O.
- Maciel, Edvaldo V. S.
- Zheng, Min
- Lermyte, Frederik
- Hausch, Felix
Ähnliche Objekte (12)
Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors
Development of the first selective proteolysis targeting chimera for the FK506-binding protein 51
Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth
Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells
Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Targeting proteolysis in viral cardiac inflammatory disease
Proteolysis targeting chimeras (PROTACs) in cancer therapy
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors
Development of the first selective proteolysis targeting chimera for the FK506-binding protein 51
Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth
Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells
Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Targeting proteolysis in viral cardiac inflammatory disease
Proteolysis targeting chimeras (PROTACs) in cancer therapy
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Discovery of a Potent Proteolysis Targeting Chimera Enables Targeting the Scaffolding Functions of FK506‐Binding Protein 51 (FKBP51)
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors
Development of the first selective proteolysis targeting chimera for the FK506-binding protein 51
Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth
Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells
Proteolysis Targeting Chimera (PROTAC) for Macrophage Migration Inhibitory Factor (MIF) Has Anti‐Proliferative Activity in Lung Cancer Cells
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Targeting proteolysis in viral cardiac inflammatory disease
Proteolysis targeting chimeras (PROTACs) in cancer therapy